In July 2023, quizartinib was approved by the FDA for use in combination with standard induction and consolidation chemotherapy in patients with newly diagnosed FLT3-ITD-mutated AML; importantly, it was also approved as monotherapy maintenance for up to 3 years in patients who do not undergo subsequent HSCT. This evidence concerns the gene FLT3 and acute myeloid leukemia.